The US Food and Drug Administration (FDA) has approved Biocon's pertuzumab-qcay (Pebrilzo), a biosimilar to pertuzumab (Perjeta), for adults with HER2-positive breast cancer in metastatic, neoadjuvant, and adjuvant treatment settings.
The approval was announced by Biocon , with the earliest licensed US launch date set as the third quarter of 2028.
For metastatic disease, pertuzumab-qcay is approved in combination with trastuzumab and docetaxel for patients who have not previously received anti-HER2 therapy or chemotherapy for metastatic breast cancer. In early breast cancer, it is approved with trastuzumab and chemotherapy for neoadjuvant treatment of locally advanced, inflammatory, or early-stage disease involving tumors larger than 2 cm or positive lymph nodes, and for adjuvant treatment of patients at high risk of recurrence.
Pertuzumab-qcay is a HER2-targeting monoclonal antibody. According to Biocon, approval was supported by structural and functional analyses, analytical similarity assessments, and comparative clinical pharmacokinetic data demonstrating high similarity to reference pertuzumab, without clinically meaningful differences in quality, safety, efficacy, or immunogenicity.
The company's accompanying safety information lists boxed warnings for left ventricular dysfunction and embryo-fetal toxicity. It recommends assessment of left ventricular ejection fraction before and during treatment and warns of serious infusion-related reactions, hypersensitivity, and anaphylaxis.
The drug is contraindicated in patients with known hypersensitivity to pertuzumab or its excipients. Common adverse reactions associated with pertuzumab-containing regimens include diarrhea, alopecia, neutropenia, nausea, fatigue, and peripheral neuropathy.
Sources:Biocon
